MY176031A - Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor - Google Patents

Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Info

Publication number
MY176031A
MY176031A MYPI2015000102A MYPI2015000102A MY176031A MY 176031 A MY176031 A MY 176031A MY PI2015000102 A MYPI2015000102 A MY PI2015000102A MY PI2015000102 A MYPI2015000102 A MY PI2015000102A MY 176031 A MY176031 A MY 176031A
Authority
MY
Malaysia
Prior art keywords
inhibitor
optionally
pi3k
raf
egfr
Prior art date
Application number
MYPI2015000102A
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Laure Moutouh-Deparseval
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY176031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MY176031A publication Critical patent/MY176031A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MYPI2015000102A 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor MY176031A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (1)

Publication Number Publication Date
MY176031A true MY176031A (en) 2020-07-22

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015000102A MY176031A (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Country Status (39)

Country Link
US (1) US9474754B2 (en, 2012)
EP (2) EP3574904A1 (en, 2012)
JP (3) JP6342396B2 (en, 2012)
KR (1) KR102112885B1 (en, 2012)
CN (1) CN104519887B (en, 2012)
AR (1) AR092045A1 (en, 2012)
AU (1) AU2013299841B8 (en, 2012)
CA (1) CA2879548C (en, 2012)
CL (1) CL2015000294A1 (en, 2012)
CO (1) CO7200273A2 (en, 2012)
CY (1) CY1122143T1 (en, 2012)
DK (1) DK2882440T3 (en, 2012)
EA (1) EA028420B1 (en, 2012)
EC (1) ECSP15008695A (en, 2012)
ES (1) ES2717911T3 (en, 2012)
GT (1) GT201500025A (en, 2012)
HK (1) HK1211831A1 (en, 2012)
HR (1) HRP20190537T1 (en, 2012)
HU (1) HUE042877T2 (en, 2012)
IL (1) IL236934B (en, 2012)
IN (1) IN2015DN00450A (en, 2012)
JO (1) JOP20130236B1 (en, 2012)
LT (1) LT2882440T (en, 2012)
MA (1) MA37829A1 (en, 2012)
MX (1) MX359403B (en, 2012)
MY (1) MY176031A (en, 2012)
NZ (1) NZ703940A (en, 2012)
PE (2) PE20150673A1 (en, 2012)
PH (1) PH12015500246B1 (en, 2012)
PL (1) PL2882440T3 (en, 2012)
PT (1) PT2882440T (en, 2012)
RS (1) RS58734B1 (en, 2012)
SG (1) SG11201500321YA (en, 2012)
SI (1) SI2882440T1 (en, 2012)
TN (1) TN2015000027A1 (en, 2012)
TR (1) TR201904980T4 (en, 2012)
TW (1) TWI607754B (en, 2012)
UA (1) UA115786C2 (en, 2012)
WO (1) WO2014025688A1 (en, 2012)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092045A1 (es) * 2012-08-07 2015-03-18 Novartis Ag Combinaciones farmaceuticas
MA38522A1 (fr) 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
WO2015193212A1 (en) * 2014-06-16 2015-12-23 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
WO2017037578A2 (en) * 2015-08-28 2017-03-09 Novartis Ag Combination therapy
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
AU2017275650B2 (en) 2016-06-03 2023-06-01 Array Biopharma Inc. Pharmaceutical combinations
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
IL270224B1 (en) 2017-05-02 2024-04-01 Novartis Ag Combination therapy employing trametinib and a defined raf inhibitor
WO2019026007A1 (en) * 2017-08-03 2019-02-07 Novartis Ag THERAPEUTIC ASSOCIATION OF THIRD GENERATION TYFRSINE KINASE INHIBITOR AND RAF INHIBITOR
IL282021B2 (en) 2018-10-05 2025-04-01 Annapurna Bio Inc Compounds and compositions for treating conditions associated with APJ receptor activity
TWI849043B (zh) * 2019-01-25 2024-07-21 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US20250108051A1 (en) * 2022-01-27 2025-04-03 Tohoku University Therapeutic agent for cancer
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
EP4593831A1 (en) * 2022-09-26 2025-08-06 Mapkure, LLC Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EA020022B1 (ru) 2007-04-10 2014-08-29 Экселиксис, Инк. Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k-альфа
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MX338856B (es) * 2009-08-24 2016-05-03 Genentech Inc Determinacion de sensibilidad de celulas al tratamiento del inhibidor de b-raf mediante la deteccion de mutacion de kras y niveles de expreson de rtk.
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EA020965B1 (ru) 2009-10-12 2015-03-31 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Способ и фармацевтическая комбинация для лечения рака
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
TR201802943T4 (tr) * 2010-11-08 2018-03-21 Novartis Ag (S)-pirolidin-1,2-dikarboksilik asit 2-amid 1-({4-metil-5-[2-(2,2,2-trifloro-1,1-dimetil-etil)-piridin-4-il]-tiyazol-2-il}amid)'in egfr'ye bağlı hastalıkların veya egfr familya üyelerini hedefleyen ajanlara karşı direnç edinmiş hastalıkların tedavisinde kullanımı.
EP2776413A1 (en) 2011-11-10 2014-09-17 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
JP6150813B2 (ja) * 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
AR092045A1 (es) * 2012-08-07 2015-03-18 Novartis Ag Combinaciones farmaceuticas

Also Published As

Publication number Publication date
MX359403B (es) 2018-09-26
IL236934B (en) 2018-11-29
EP2882440B1 (en) 2019-02-27
DK2882440T3 (da) 2019-05-06
ECSP15008695A (es) 2019-03-29
EA028420B1 (ru) 2017-11-30
RS58734B1 (sr) 2019-06-28
PH12015500246A1 (en) 2015-03-30
JP2018109022A (ja) 2018-07-12
CN104519887B (zh) 2017-06-27
PT2882440T (pt) 2019-04-23
AR092045A1 (es) 2015-03-18
MA37829A1 (fr) 2017-01-31
JP2020019780A (ja) 2020-02-06
CA2879548C (en) 2020-07-21
CY1122143T1 (el) 2020-11-25
HK1211831A1 (zh) 2016-06-03
MX2015001732A (es) 2015-06-03
SG11201500321YA (en) 2015-04-29
CN104519887A (zh) 2015-04-15
PE20150673A1 (es) 2015-05-20
JP6595024B2 (ja) 2019-10-23
BR112015002384A8 (pt) 2023-01-31
HRP20190537T1 (hr) 2019-06-28
GT201500025A (es) 2017-09-28
UA115786C2 (uk) 2017-12-26
AU2013299841A1 (en) 2015-02-12
IN2015DN00450A (en, 2012) 2015-06-26
PL2882440T3 (pl) 2019-07-31
AU2013299841A8 (en) 2017-01-05
JP6342396B2 (ja) 2018-06-13
KR20150040905A (ko) 2015-04-15
US20150265616A1 (en) 2015-09-24
JOP20130236B1 (ar) 2021-08-17
ES2717911T3 (es) 2019-06-26
JP6974669B2 (ja) 2021-12-01
AU2013299841B2 (en) 2016-11-24
HK1204976A1 (en) 2015-12-11
TR201904980T4 (tr) 2019-05-21
AU2013299841B8 (en) 2017-01-05
EP2882440A1 (en) 2015-06-17
WO2014025688A1 (en) 2014-02-13
EA201590332A1 (ru) 2015-06-30
TN2015000027A1 (en) 2016-06-29
SI2882440T1 (sl) 2019-05-31
LT2882440T (lt) 2019-04-25
KR102112885B1 (ko) 2020-05-19
HUE042877T2 (hu) 2019-07-29
US9474754B2 (en) 2016-10-25
PH12015500246B1 (en) 2015-03-30
CO7200273A2 (es) 2015-02-27
EP3574904A1 (en) 2019-12-04
NZ703940A (en) 2018-04-27
CL2015000294A1 (es) 2015-05-08
CA2879548A1 (en) 2014-02-13
TWI607754B (zh) 2017-12-11
PE20191655A1 (es) 2019-11-07
JP2015524472A (ja) 2015-08-24
TW201410247A (zh) 2014-03-16
BR112015002384A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
MY176031A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
AU2011328009A8 (en) Compounds and methods for treating pain
MX2016008362A (es) Combinaciones farmaceuticas.
MX2014010590A (es) Terapia de combinacion para trastornos proliferativos.
NZ730763A (en) Methods of treating a tauopathy
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EA201500314A1 (ru) Лекарственные формы энзалутамида
UA117451C2 (uk) Терапевтично активні сполуки і способи їх застосування
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
NZ707086A (en) Anti-cd40 antibodies and methods of use
HK1214765A1 (zh) 包含b-raf抑制剂和组蛋白脱乙酰基酶抑制剂的药物组合以及其在治疗增生性疾病中的用途
MX366130B (es) Inhibidores bivalentes de las proteinas iap y métodos terapéuticos que usan los mismos.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX360189B (es) Terapia de combinacion para el tratamiento de glioblastoma.
PH12012500916B1 (en) Treatments for gastrointestinal disorders
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
PH12015501002A1 (en) Treatment of cancer with pomalidomide in a renally impaired subject
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
MX2019013864A (es) Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
UA86338U (ru) Способ лечения беременных с гестационным диабетом